Outcome of small node-negative ER+/HER2+and ER-/HER2+breast cancers might be different

被引：0
|
作者：
Altundag, Kadri [1 ]
机构：
[1] MKA Breast Canc Clin, Ankara, Turkey
来源：
JOURNAL OF BUON | 2020年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：583 / 583
页数：1
相关论文
共 50 条
  • [31] A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells
    Atmaca, Harika
    Bozkurt, Emir
    Uzunoglu, Selim
    Uslu, Ruchan
    Karaca, Burcak
    TOXICOLOGY LETTERS, 2013, 221 (02) : 128 - 136
  • [32] A DIVERSE INDUCTION OF APOPTOSIS BY TRABECTEDIN IN MCF-7 (HER2-/ER+) AND MDA-MB-453 (HER2+/ER-) BREAST CANCER CELLS
    Atmaca, H.
    Bozkurt, E.
    Uzunoglu, S.
    Uslu, R.
    Karaca, B.
    ANNALS OF ONCOLOGY, 2013, 24 : 31 - 31
  • [33] ER(+)/HER2(+) and ER−/HER2(+) breast cancers might have different intracranial recurrence patterns after brain-directed radiation for brain metastases
    Kadri Altundag
    Breast Cancer Research and Treatment, 2019, 177 : 233 - 233
  • [34] The influence of ER on small HER2-positive invasive breast cancers
    Caggiano, V.
    Parise, C.
    Bauer, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Tamoxifen, HER2, and Endoxifen: The Role of CYP2D6 as a Predictor of Tamoxifen Resistance in ER+/HER2+Breast Cancer
    Goetz, M. P.
    Reinicke, K. E.
    Reid, J. M.
    Suman, V. J.
    Kuffel, M. J.
    Safgren, S. L.
    Buhrow, S. A.
    Reynolds, C. A.
    Jenkins, R. B.
    Hawse, J. R.
    Perez, E. A.
    Ingle, J. N.
    Ames, M. M.
    CANCER RESEARCH, 2009, 69 (24) : 594S - 594S
  • [36] Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR−/HER2+ breast cancer subtypes
    Wu Ding
    Dengfeng Ye
    Haifeng Chen
    Yingli Lin
    Zhian Li
    Chuanjian Tu
    Breast Cancer, 2024, 31 : 295 - 304
  • [37] β2-microglobulin has a different regulatory molecular mechanism between ER+ and ER− breast cancer with HER2−
    Dandan Chai
    Kesheng Li
    Huifen Du
    Suisheng Yang
    Rong Yang
    Yang Xu
    Xiaowen Lian
    BMC Cancer, 19
  • [38] Complete disappearance of ER+/HER2+breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition
    Arpino, G
    Weiss, H
    Wakeling, AE
    Osborne, K
    Schiff, R
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S15 - S15
  • [39] Comparison of the sensitivity to endocrine therapy of PR plus /ER- patients and ER plus /PR- patients with HER2+breast cancer
    Hao, X.
    Liu, Y.
    Hui, R.
    Zhang, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Targeted therapies for ER+/HER2-metastatic breast cancer
    Yamamoto-Ibusuki, Mutsuko
    Arnedos, Monica
    Andre, Fabrice
    BMC MEDICINE, 2015, 13
12345